NCT00118248

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Detailed description

PRIMARY OBJECTIVES: I. Determine the 1-year treatment failure rate in patients with inoperable locoregionally advanced or metastatic medullary or differentiated thyroid carcinoma treated with 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) (tanespimycin). SECONDARY OBJECTIVES: I. Determine the toxicity of this drug in these patients. Determine the 1-year progression-free rate in patients treated with this drug. II. Determine the response rate and duration of response in patients treated with this drug. III. Determine the time to treatment failure and time to subsequent therapy in patients treated with this drug. IV. Determine the time to disease progression and overall survival of patients treated with this drug. V. Correlate the incidence rate of RAS, RAF, and RET mutations with clinical outcome in patients treated with this drug. OUTLINE: This is a multicenter study. Patients are stratified according to type of thyroid carcinoma (medullary vs differentiated). Patients receive tanespimycin intravenously (IV) over 2-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years from study entry.

Conditions

• Recurrent Thyroid Cancer
• Stage IV Follicular Thyroid Cancer
• Stage IV Papillary Thyroid Cancer
• Thyroid Gland Medullary Carcinoma

Interventions

Type	Name	Description
DRUG	tanespimycin	Given IV

Timeline

• Start date: 2004-12-01
• Primary completion: 2009-08-01
• Completion: 2012-04-01
• First posted: 2005-07-11
• Last updated: 2017-02-15
• Results posted: 2014-05-06

Locations

1 site across 1 country: United States